“Hemophilia B Epidemiology” has been added to DelveInsight
Overview of Hemophilia B Epidemiology, pathophysiology, various diagnostic approaches, and treatment algorithm, including detailed chapters for marketed products and emerging therapies
Request free sample copy here- https://www.delveinsight.com/sample-request/hemophilia-b-epidemiology-forecast
Important facts of Hemophilia B Epidemiology Report
Hemophilia B Epidemiology Cause
The primary cause behind this disorder is a mutation or change, in Factor IX gene, that provides instructions for making the clotting factor proteins. On the X chromosome, the hemophilia mutation is located, meaning mothers pass this genetic defect on to their children; therefore it is called X-linked inheritance.
Hemophilia B Treatment
The most common treatment for hemophilia B is called Replacement therapy. Concentrates of clotting factor IX are the foundation of this treatment and are administered as an infusion. BeneFIX, Rixubis, Ixinity, Alprolix, Idelvion, and Rebinyn are the some available recombinant factor IX products in the US. Plasma-Derived Factor IX Concentrates and Fresh Frozen Plasma is also used for the treatment.
Hemophilia B Epidemiology Segmentation
Hemophilia B Epidemiology: Report Scope
Following is the table of content of Hemophilia B report
1. Key Insights
2. Executive Summary of Hemophilia B
3. Hemophilia B: Disease Background and Overview
4. Patient Journey
5. Epidemiology and Patient Population
5.5. EU-5 Country-wise Epidemiology
6. Treatment Algorithm, Current Treatment, and Medical Practices
7. KOL Views
8. Unmet Needs
9. Appendix
10. DelveInsight Capabilities
11. Disclaimer
12. About DelveInsight
Hemophilia B Epidemiology: Reasons to buy
The Hemophilia B Epidemiology report will allow the user to –
Related Reports
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: +919650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/